Baader Bank Aktiengesellschaft’s Mereo BioPharma MREO Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,330	Closed	-$2.67K	–	490
2026 Q1	$2.67K	Sell	12,330 -116,412	-90%	-$50K	﹤0.01%	416
2025 Q4	$33.1K	Buy	+128,742	New	+$245K	﹤0.01%	421

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Baader Bank Aktiengesellschaft's MREO Position: Q2 2026 in Review

Baader Bank Aktiengesellschaft sold out of Mereo BioPharma (MREO) in Q2 2026, closing a stake of 12,330 shares — an estimated $2.67K sold.

Baader Bank Aktiengesellschaft first reported a position in MREO in Q4 2025 and held it in 2 quarters. The position peaked at $33.1K in Q4 2025. 61 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

Baader Bank Aktiengesellschaft reported no remaining Mereo BioPharma position as of Q2 2026 after selling out during the quarter.
Baader Bank Aktiengesellschaft sold 12,330 Mereo BioPharma shares in Q2 2026, an estimated $2.67K.
Baader Bank Aktiengesellschaft first reported a position in Mereo BioPharma in Q4 2025 and held it in 2 quarters.
Baader Bank Aktiengesellschaft's Mereo BioPharma position peaked at $33.1K in Q4 2025.
61 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q2 2026, filed 23 Jul 2026.